Memory and brain health after 50, by the evidence: what protects cognition and what does not

If you are over 50 and you walk into a room and forget why, that moment can feel like a warning. Most of the time it is not. Some slowing of memory and word-finding is a normal part of aging. A smaller number of people develop mild cognitive impairment, and fewer still progress to dementia. The good news from the research is that a meaningful share of dementia risk tracks with factors people can influence. The sobering part is that many of the products sold to protect your brain fail when they are put to a fair test. This overview lays out what the evidence supports, what it does not, and where the real uncertainty still sits.

Normal aging, MCI, and dementia are three different things

Normal age-related change is real and common. Processing speed drops. Names take longer to surface. You rely more on lists. Crucially, day-to-day function stays intact, and the pattern is stable rather than steadily worsening.

Mild cognitive impairment (MCI) is a step beyond that. It means measurable decline in memory or thinking that is greater than expected for someone’s age, but not severe enough to derail independent living. MCI is not a guarantee of dementia. Some people with MCI stay stable for years, and some revert toward normal. Others progress. Clinical guidelines treat MCI as a signal to look for treatable contributors, not as a diagnosis of dementia (Petersen et al., Neurology, 2018).

Dementia is diagnosed when decline in memory or other thinking skills is severe enough to interfere with everyday independence. Alzheimer’s disease is the most common cause, but it is not the only one. The line that matters for families is function: can the person manage finances, medications, and daily tasks safely.

The biggest lever is managing risk factors, not buying a product

The most influential summary of prevention evidence comes from the Lancet Commission on dementia. In its 2020 report, the Commission estimated that around 40 percent of dementia cases worldwide are associated with a group of modifiable risk factors across the life course (Livingston et al., Lancet, 2020). Its 2024 update added further factors and raised that figure to roughly 45 percent (Livingston et al., Lancet, 2024).

A few points keep this in perspective. “Associated with” is a population estimate, not a promise for any one person. It does not mean 45 percent of cases would vanish if everyone acted, and much of the risk is set earlier in life. Genetics and age still matter and are outside anyone’s control. Even so, the direction is consistent: the factors on the Commission’s list are ordinary health and lifestyle targets, not exotic ones. That reframes brain health away from a pill and toward the same things that protect the heart and the blood vessels.

FINGER: the clearest positive trial

The FINGER trial is the result most often cited when researchers argue that prevention can work. Investigators in Finland randomized about 1,260 older adults at elevated risk to either a structured multidomain program or general health advice. The program combined several changes at once rather than testing one in isolation. After two years, the group in the intensive program did better on a battery of cognitive tests than the control group (Ngandu et al., Lancet, 2015).

The effect was modest, and the trial measured test performance over two years rather than dementia diagnoses over decades. It also bundled multiple components together, so it cannot tell you which piece did the work. But as a randomized test of the “stack several healthy changes” idea, FINGER stands out because it came back positive. It has since inspired similar multidomain trials in other countries, with more mixed results, which is part of why researchers remain cautious rather than triumphant.

SPRINT MIND: a real signal, and a missed primary endpoint

Blood pressure is one of the risk factors on the Lancet list, and it has been tested directly. SPRINT MIND drew on the large SPRINT blood pressure trial, comparing intensive control (a lower systolic target) with standard control in adults with hypertension. Intensive treatment significantly reduced the rate of mild cognitive impairment. It also reduced a combined measure of MCI plus probable dementia (SPRINT MIND Investigators, JAMA, 2019).

The headline caveat matters. The trial’s primary endpoint was probable all-cause dementia on its own, and on that specific measure the reduction did not reach statistical significance. The trial ended earlier than planned and produced fewer dementia cases than expected, which left it underpowered for that outcome. So the fair reading is nuanced: strong evidence for a benefit on MCI, and a suggestive but unproven signal for dementia itself. It is a good example of why the primary endpoint, not the most flattering secondary result, sets the ceiling on what a trial proves.

What does not hold up in trials

Most supplements marketed for memory have failed fair tests. In a large randomized trial, ginkgo biloba did not reduce the rate of dementia or Alzheimer’s disease in older adults (DeKosky et al., JAMA, 2008). Omega-3 supplements did not slow cognitive decline in a large trial that tracked cognition as a secondary outcome (Chew et al., JAMA, 2015). Evidence for individual vitamins is thin and inconsistent, and a supplement facing weak regulation can be sold on a hopeful label long after the trials come back flat.

Commercial brain-training claims are weaker than the ads suggest. Cognitive training can improve the specific skill you practice. The problem is transfer. In the large ACTIVE trial, training improved the trained abilities but did not broadly carry over to untrained everyday function in the way marketing often implies (Ball et al., JAMA, 2002). “You got better at the game” is not the same as “your brain is protected.”

Even sensible-sounding lifestyle bets can miss. A structured physical activity program did not significantly reduce cognitive impairment compared with a health education program in one large trial of older adults (Sink et al., JAMA, 2015). A randomized trial of the MIND diet, a pattern designed for brain health, did not show a significant cognitive benefit over a mild calorie-restriction comparison over three years (Barnes et al., New England Journal of Medicine, 2023). None of this means exercise or diet are worthless for overall health. It means the strong observational signals do not always survive a randomized test, and readers deserve to know when that happens.

How this hub is organized

This overview sits above four more detailed articles, each focused on one part of the picture. One covers exercise and what movement trials do and do not show for cognition. One covers diet, including where observational patterns and randomized trials disagree. One covers supplements, walking through the products with the loudest claims and the quietest evidence. And one covers the modifiable risk factors from the Lancet Commission in more depth, including blood pressure, hearing, and the rest of the list.

Read them as a set. The recurring lesson is that brain health after 50 is mostly the sum of unglamorous, well-studied habits and treated medical conditions, and that the shortcuts sold as brain protection tend to be the parts with the least evidence behind them.

This article reports what published trials and expert reviews have found. It is not medical advice, and it does not recommend any test, target, dose, or treatment for you. Cognitive symptoms have many possible causes, some of them treatable, and only a clinician who can evaluate you directly can sort out which apply. If you are worried about your memory or a family member’s, that conversation belongs with a qualified health professional.

Common questions

Is forgetting names and losing my keys a sign of dementia?

On its own, usually not. Slower recall and occasional lapses are common with normal aging, and they tend to stay stable rather than steadily worsen. The features that concern clinicians are decline that is clearly greater than expected for your age and, especially, changes that start to interfere with managing daily tasks. A pattern that is getting noticeably worse over months, or that others are noticing, is worth raising with a health professional.

Does the 40 to 45 percent figure mean I can prevent almost half of my dementia risk?

No. That number from the Lancet Commission is a population-level estimate of the share of cases associated with modifiable risk factors across the whole life course (Livingston et al., Lancet, 2020; Livingston et al., Lancet, 2024). It is not a personal guarantee, much of the risk is shaped earlier in life, and age and genetics still matter and cannot be changed. It is best read as evidence that these factors are worth attention, not as a promise of a specific outcome for any individual.

If FINGER was positive, why are researchers still cautious?

FINGER showed a modest improvement on cognitive tests over two years, not a reduction in dementia diagnoses over decades (Ngandu et al., Lancet, 2015). It also combined several changes at once, so it cannot say which part mattered. Later trials built on the same idea have produced more mixed results. That combination, a real but limited positive finding plus inconsistent follow-up trials, is why the field treats multidomain prevention as promising rather than settled.

Did SPRINT MIND prove blood pressure control prevents dementia?

Not fully. Intensive blood pressure control significantly reduced mild cognitive impairment in the trial, and reduced a combined MCI-plus-dementia measure (SPRINT MIND Investigators, JAMA, 2019). But the study’s main outcome was dementia by itself, and on that specific measure the reduction did not reach statistical significance, partly because the trial ended early with fewer dementia cases than expected. So the evidence is strong for MCI and suggestive but unproven for dementia.

Are any supplements or brain-training apps worth it for memory?

The randomized evidence is discouraging. Ginkgo did not reduce dementia (DeKosky et al., JAMA, 2008), and omega-3 supplements did not slow cognitive decline in a large trial (Chew et al., JAMA, 2015). Brain-training tends to improve the specific task you practice without broadly transferring to everyday function (Ball et al., JAMA, 2002). This article does not tell you what to take or use; it reports that these popular options have generally not held up when tested.